INCB161734's high selectivity for the G12D mutation avoids the toxicities common in pan-RAS inhibitors. This superior safety profile is a key strategic advantage, as it allows the drug to be combined with standard first-line chemotherapy, a feat that is difficult for less selective agents.
The advent of selective G12D inhibitors will fundamentally split the treatment paradigm for pancreatic cancer. Patients with G12D mutations will likely receive these inhibitors combined with chemo upfront, while patients with other RAS mutations will follow a different therapeutic sequence.
The trial's design strategically allows for chemotherapy to be reduced or stopped due to toxicity while the patient continues on the G12D inhibitor. This positions the experimental drug not just as an add-on, but as a potential long-term maintenance backbone for treatment.
The speaker predicts that if the G12D inhibitor and chemotherapy combination proves successful in the metastatic setting, its high response rate and safety profile will make it a compelling option for earlier stages of the disease, such as in neoadjuvant settings for resectable cancers.